Bad Münster am Stein-Ebernburg, Germany
Bad Münster am Stein-Ebernburg, Germany

Time filter

Source Type

News Article | November 11, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA),route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Influenza A Virus, H1N1 Subtype Infections - Pipeline Review,H2 2016 addition with 61 market data tables and 17 figures, spread across 191 pages is available at http://www.rnrmarketresearch.com/influenza-a-virus-h1n1-subtype-infections-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries,conferences,SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. AbbVie Inc ,Akshaya Bio Inc.,Altimmune, Inc.,Antigen Express, Inc.,Beijing Minhai Biotechnology Co., Ltd,CEL-SCI Corporation,Cilian AG ,ContraFect Corporation,EpiVax, Inc. ,Etubics CorporationGemmus Pharma Inc.,iBio, Inc. ,ILiAD Biotechnologies, LLC,Inovio Pharmaceuticals, Inc.,Johnson & Johnson,Kineta, Inc. ,Kyowa Hakko Kirin Co., Ltd.,Lakewood-Amedex Inc,Medicago Inc. ,MedImmune, LLC,Microbiotix, Inc.,Mucosis B.V. ,NanoViricides, Inc. Inquire before buying http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748001(This is a premium report price at US$2000 for a single user PDF license).


News Article | November 24, 2016
Site: www.PR.com

Report provides comprehensive information and pipeline landscape on the therapeutic development for Malaria with relative analysis at various stages which include drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Albany, NY, November 24, 2016 --( Request for Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873462 The report begins with the detailed introduction of malaria disease along with its cure and symptoms. Malaria is a life-threatening blood disease caused by a parasite that is transmitted to humans after the bit of an infected female Anopheles mosquito. The disease is infectious for every individual but mostly increases risk for people such as young children and infants, travelers coming from areas with no malaria, pregnant women and their unborn children. Every year, 350 to 500 million cases of malaria occur world-wide and over one million people die due to malaria. Symptoms of Malaria include - fever, headache, sweat, fatigue, enlarged spleen, nausea and vomiting. Finest treatment for the disease includes anti-malarial medicines and healthy lifestyle. Further, pipeline guide also features descriptive drug profiles for the pipeline elements containing product description, descriptive licensing and collaboration details along with R&D and other developmental activities. The guide also covers the pipeline products that are based on numerous stages of development ranging from pre-registration till discovery and undisclosed stages. Following are some of the prime pharmaceutical drugs used by emerging players to prevent malaria- Atovaquone proguanil Doxycycline Mefloquine Chloroquine Primaquine Browse Full Info with TOC: http://www.marketresearchhub.com/report/malaria-pipeline-review-h2-2016-report.html The Malaria pipeline guide also reviews the key players involved in therapeutic development for malaria and features inactive and discontinued projects. Additionally, various dynamic tracking process also ensures that most recent developments are captured on a real time basis. Some of the key players mentioned in the report are: Acetylon Pharmaceuticals, Inc. Cellceutix Corporation Chong Kun Dang Pharmaceutical Corp. Cilian AG SBI Pharmaceuticals Co., Ltd. Microbiotix, Inc. Zydus Cadla Healthcare Limited and others. The buyer can also gain benefits and develop tactical initiatives by understanding the focus areas of leading companies. In fact, they can also design in-licensing and out-licensing policies by identifying future partners with attractive projects to expand business potential. About Us Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Us 90 State Street Albany, NY 12207 United States Toll Free : 866-997-4948 (US-Canada) Tel : +1-518-621-2074 Email : press@marketresearchhub.com Website : http://www.marketresearchhub.com Albany, NY, November 24, 2016 --( PR.com )-- A latest pharmaceutical and healthcare disease pipeline guide by Global Markets Direct has been launched and added to the vast archive of Market Research Hub (MRH). The report is titled “Malaria - Pipeline Review, H2 2016,” provides comprehensive information and pipeline landscape on the therapeutic development for Malaria with relative analysis at various stages which include drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The research study of 413 pages, built using proprietary databases along with latest updatesand featured news & press releases from various university sites and industry specific third party sources.Request for Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873462The report begins with the detailed introduction of malaria disease along with its cure and symptoms. Malaria is a life-threatening blood disease caused by a parasite that is transmitted to humans after the bit of an infected female Anopheles mosquito. The disease is infectious for every individual but mostly increases risk for people such as young children and infants, travelers coming from areas with no malaria, pregnant women and their unborn children. Every year, 350 to 500 million cases of malaria occur world-wide and over one million people die due to malaria.Symptoms of Malaria include - fever, headache, sweat, fatigue, enlarged spleen, nausea and vomiting. Finest treatment for the disease includes anti-malarial medicines and healthy lifestyle.Further, pipeline guide also features descriptive drug profiles for the pipeline elements containing product description, descriptive licensing and collaboration details along with R&D and other developmental activities. The guide also covers the pipeline products that are based on numerous stages of development ranging from pre-registration till discovery and undisclosed stages.Following are some of the prime pharmaceutical drugs used by emerging players to prevent malaria-Atovaquone proguanilDoxycyclineMefloquineChloroquinePrimaquineBrowse Full Info with TOC: http://www.marketresearchhub.com/report/malaria-pipeline-review-h2-2016-report.htmlThe Malaria pipeline guide also reviews the key players involved in therapeutic development for malaria and features inactive and discontinued projects. Additionally, various dynamic tracking process also ensures that most recent developments are captured on a real time basis. Some of the key players mentioned in the report are:Acetylon Pharmaceuticals, Inc.Cellceutix CorporationChong Kun Dang Pharmaceutical Corp.Cilian AGSBI Pharmaceuticals Co., Ltd.Microbiotix, Inc.Zydus Cadla Healthcare Limited and others.The buyer can also gain benefits and develop tactical initiatives by understanding the focus areas of leading companies. In fact, they can also design in-licensing and out-licensing policies by identifying future partners with attractive projects to expand business potential.About UsMarket Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Us90 State StreetAlbany, NY 12207United StatesToll Free : 866-997-4948 (US-Canada)Tel : +1-518-621-2074Email : press@marketresearchhub.comWebsite : http://www.marketresearchhub.com Click here to view the list of recent Press Releases from Market Research Hub


Calow J.,Cilian AG | Behrens A.-J.,University of Oxford | Mader S.,Cilian AG | Bockau U.,Cilian AG | And 8 more authors.
mAbs | Year: 2016

Antibody glycosylation is a key parameter in the optimization of antibody therapeutics. Here, we describe the production of the anti-cancer monoclonal antibody rituximab in the unicellular ciliate, Tetrahymena thermophila. The resulting antibody demonstrated enhanced antibody-dependent cell-mediated cytotoxicity, which we attribute to unusual N-linked glycosylation. Detailed chromatographic and mass spectrometric analysis revealed afucosylated, oligomannose-type glycans, which, as a whole, displayed isomeric structures that deviate from the typical human counterparts, but whose branches were equivalent to fragments of metabolic intermediates observed in human glycoproteins. From the analysis of deposited crystal structures, we predict that the ciliate glycans adopt protein-carbohydrate interactions with the Fc domain that closely mimic those of native complex-type glycans. In addition, terminal glucose structures were identified that match biosynthetic precursors of human glycosylation. Our results suggest that ciliate-based expression systems offer a route to large-scale production of monoclonal antibodies exhibiting glycosylation that imparts enhanced cell killing activity. © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC © Cilian AG.


Aldag I.,Cilian AG | Bockau U.,Cilian AG | Rossdorf J.,Cilian AG | Laarmann S.,Carl Zeiss GmbH | And 4 more authors.
BMC Biotechnology | Year: 2011

Background: Tetrahymena thermophila possesses many attributes that render it an attractive host for the expression of recombinant proteins. Surface proteins from the parasites Ichthyophthirius multifiliis and Plasmodium falciparum and avian influenza virus antigen H5N1 were displayed on the cell membrane of this ciliate. Furthermore, it has been demonstrated that T. thermophila is also able to produce a functional human DNase I. The present study investigates the heterologous expression of the functional human intestinal alkaline phosphatase (hiAP) using T. thermophila and thereby presents a powerful tool for the optimization of the ciliate-based expression system.Results: Functional and full length human intestinal alkaline phosphatase was expressed by T. thermophila using a codon-adapted gene containing the native signal-peptide and GPI (Glycosylphosphatidylinositol) anchor attachment signal. HiAP activity in the cell extract of transformants suggested that the hiAP gene was successfully expressed. Furthermore, it was demonstrated that the enzyme was modified with N-glycosylation and localized on the surface membrane by the C-terminal GPI anchor. A C-terminally truncated version of hiAP lacking the GPI anchor signal peptide was secreted into the medium as an active enzyme. In a first approach to establish a high level expression system up to 14,000 U/liter were produced in a time frame of two days, which exceeds the production rate of other published expression systems for this enzyme.Conclusions: With the expression of hiAP, not only a protein of commercial interest could be produced, but also a reporter enzyme that offers the possibility to analyze T. thermophila genes that play a role in the regulation of protein secretion. Additionally, the fact that ciliates do not secrete an endogenous alkaline phosphatase provides the possibility to use the truncated hiAP as a reporter enzyme, allowing the quantification of measures that will be necessary for further optimization of the host strains and the fermentation processes. © 2011 Aldag et al; licensee BioMed Central Ltd.


Cowan G.J.M.,University of Edinburgh | Bockau U.,Cilian AG | Eleni-Muus J.,Cilian AG | Aldag I.,Cilian AG | And 4 more authors.
PLoS ONE | Year: 2014

Development of effective malaria vaccines is hampered by the problem of producing correctly folded Plasmodium proteins for use as vaccine components. We have investigated the use of a novel ciliate expression system, Tetrahymena thermophila, as a P. falciparum vaccine antigen platform. A synthetic vaccine antigen composed of N-terminal and C-terminal regions of merozoite surface protein-1 (MSP-1) was expressed in Tetrahymena thermophila. The recombinant antigen was secreted into the culture medium and purified by monoclonal antibody (mAb) affinity chromatography. The vaccine was immunogenic in MF1 mice, eliciting high antibody titers against both N- and C-terminal components. Sera from immunized animals reacted strongly with P. falciparum parasites from three antigenically different strains by immunofluorescence assays, confirming that the antibodies produced are able to recognize parasite antigens in their native form. Epitope mapping of serum reactivity with a peptide library derived from all three MSP-1 Block 2 serotypes confirmed that the MSP-1 Block 2 hybrid component of the vaccine had effectively targeted all three serotypes of this polymorphic region of MSP-1. This study has successfully demonstrated the use of Tetrahymena thermophila as a recombinant protein expression platform for the production of malaria vaccine antigens. © 2014 Cowan et al.


Patent
Cilian Ag | Date: 2011-03-02

The present invention is related to a system for the heterologous expression of a monoclonal Antibody (mAb) or a fragment or derivative thereof, said system comprising at least one ciliate host cell, and incorporated, into said ciliate host cell, at least one heterologous nucleic acid molecule encoding for said monoclonal Antibody, or a fragment or derivative thereof.


PubMed | Cell Therapy Group, Cilian AG and University of Edinburgh
Type: Journal Article | Journal: PloS one | Year: 2014

Development of effective malaria vaccines is hampered by the problem of producing correctly folded Plasmodium proteins for use as vaccine components. We have investigated the use of a novel ciliate expression system, Tetrahymena thermophila, as a P. falciparum vaccine antigen platform. A synthetic vaccine antigen composed of N-terminal and C-terminal regions of merozoite surface protein-1 (MSP-1) was expressed in Tetrahymena thermophila. The recombinant antigen was secreted into the culture medium and purified by monoclonal antibody (mAb) affinity chromatography. The vaccine was immunogenic in MF1 mice, eliciting high antibody titers against both N- and C-terminal components. Sera from immunized animals reacted strongly with P. falciparum parasites from three antigenically different strains by immunofluorescence assays, confirming that the antibodies produced are able to recognize parasite antigens in their native form. Epitope mapping of serum reactivity with a peptide library derived from all three MSP-1 Block 2 serotypes confirmed that the MSP-1 Block 2 hybrid component of the vaccine had effectively targeted all three serotypes of this polymorphic region of MSP-1. This study has successfully demonstrated the use of Tetrahymena thermophila as a recombinant protein expression platform for the production of malaria vaccine antigens.


Tetrahymena thermophila possesses many attributes that render it an attractive host for the expression of recombinant proteins. Surface proteins from the parasites Ichthyophthirius multifiliis and Plasmodium falciparum and avian influenza virus antigen H5N1 were displayed on the cell membrane of this ciliate. Furthermore, it has been demonstrated that T. thermophila is also able to produce a functional human DNase I. The present study investigates the heterologous expression of the functional human intestinal alkaline phosphatase (hiAP) using T. thermophila and thereby presents a powerful tool for the optimization of the ciliate-based expression system.Functional and full length human intestinal alkaline phosphatase was expressed by T. thermophila using a codon-adapted gene containing the native signal-peptide and GPI (Glycosylphosphatidylinositol) anchor attachment signal. HiAP activity in the cell extract of transformants suggested that the hiAP gene was successfully expressed. Furthermore, it was demonstrated that the enzyme was modified with N-glycosylation and localized on the surface membrane by the C-terminal GPI anchor. A C-terminally truncated version of hiAP lacking the GPI anchor signal peptide was secreted into the medium as an active enzyme. In a first approach to establish a high level expression system up to 14,000 U/liter were produced in a time frame of two days, which exceeds the production rate of other published expression systems for this enzyme.With the expression of hiAP, not only a protein of commercial interest could be produced, but also a reporter enzyme that offers the possibility to analyze T. thermophila genes that play a role in the regulation of protein secretion. Additionally, the fact that ciliates do not secrete an endogenous alkaline phosphatase provides the possibility to use the truncated hiAP as a reporter enzyme, allowing the quantification of measures that will be necessary for further optimization of the host strains and the fermentation processes.

Loading Cilian AG collaborators
Loading Cilian AG collaborators